A
Anna Wurtz
Researcher at Yale University
Publications - 21
Citations - 1433
Anna Wurtz is an academic researcher from Yale University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 10, co-authored 17 publications receiving 908 citations. Previous affiliations of Anna Wurtz include Yale Cancer Center.
Papers
More filters
Journal ArticleDOI
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott N. Gettinger,Jungmin Choi,Katherine Hastings,Anna Truini,Ila Datar,Ryan T. Sowell,Anna Wurtz,Weilai Dong,Guoping Cai,Mary Ann Melnick,Victor Y. Du,Joseph Schlessinger,Sarah B. Goldberg,Anne C. Chiang,Miguel F. Sanmamed,Ignacio Melero,Jackeline Agorreta,Luis M. Montuenga,Richard P. Lifton,Soldano Ferrone,Paula B. Kavathas,David L. Rimm,Susan M. Kaech,Kurt A. Schalper,Roy S. Herbst,Katerina Politi +25 more
TL;DR: CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs.
Journal ArticleDOI
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux,Scott N. Gettinger,Grainne M. O'Kane,Kathryn C. Arbour,Joel W. Neal,Hatim Husain,Tracey L. Evans,Julie R. Brahmer,Alona Muzikansky,Philip Bonomi,Salvatore Del Prete,Anna Wurtz,Anna F. Farago,Dora Dias-Santagata,Mari Mino-Kenudson,Karen L. Reckamp,Helena A. Yu,Heather A. Wakelee,Frances A. Shepherd,Zofia Piotrowska,Lecia V. Sequist +20 more
TL;DR: There is a growing appreciation that EGFR-mutant NSCLCs can undergo SCLC transformation, and it is demonstrated that this occurs at an average of 17.8 months after diagnosis and cases are often characterized by Rb1, TP53, and PIK3CA mutations.
Journal ArticleDOI
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Katherine Hastings,Helena A. Yu,Helena A. Yu,Wei Wei,Francisco Sanchez-Vega,Michelle DeVeaux,Jungmin Choi,Hira Rizvi,Aaron Lisberg,A. Truini,Christine A. Lydon,Zongzhi Liu,B.S. Henick,B.S. Henick,Anna Wurtz,Guoping Cai,Andrew J. Plodkowski,Niamh Long,Darragh Halpenny,J. Killam,Isabel B. Oliva,Nikolaus Schultz,Gregory J. Riely,Gregory J. Riely,Maria E. Arcila,M. Ladanyi,Daniel Zelterman,Roy S. Herbst,Roy S. Herbst,Sarah B. Goldberg,Sarah B. Goldberg,Mark M. Awad,Edward B. Garon,Scott N. Gettinger,Scott N. Gettinger,Matthew D. Hellmann,Matthew D. Hellmann,Katerina Politi,Katerina Politi +38 more
TL;DR: Understanding the heterogeneity of EGFR mutant tumors may be informative for establishing the benefits and uses of PD-(L)1 therapies for patients with this disease.
Journal ArticleDOI
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
Elza C. de Bruin,Catherine F. Cowell,Patricia H. Warne,Ming Jiang,Rebecca E. Saunders,Mary Ann Melnick,Scott N. Gettinger,Zenta Walther,Anna Wurtz,Guus J. J. E. Heynen,Daniëlle A.M. Heideman,Jose Javier Gomez-Roman,Almudena García-Castaño,Yixuan Gong,Marc Ladanyi,Harold E. Varmus,René Bernards,Egbert F. Smit,Katerina Politi,Julian Downward +19 more
TL;DR: A subgroup of patients with EG FR-mutant lung adenocarcinoma who might benefit from combination therapy with EGFR and MEK inhibitors are identified.
Journal ArticleDOI
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
Scott N. Gettinger,Anna Wurtz,Sarah B. Goldberg,David L. Rimm,Kurt A. Schalper,Susan M. Kaech,Paula Kavathas,Anne C. Chiang,Rogerio Lilenbaum,Daniel Zelterman,Katerina Politi,Roy S. Herbst +11 more
TL;DR: Acquired resistance to PD‐1 axis inhibitors is often limited to one or two sites when local therapy and continuation of PD-1 axis inhibitor therapy can result in prolonged benefit, and LN metastases appear to be particularly susceptible sites to AR.